Th9 Cells as Targets for Immunotherapy

O. Awe, Mark Kaplan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The secretion of specific cytokines distinguishes T helper cell subsets and confers the ability of the T cell to promote distinct types of inflammation. The restricted nature of cytokine production among these subsets makes them attractive therapeutic targets. The interleukin (IL)-9-secreting subset termed Th9 cells are observed in patients and in mouse models associated with immunity to parasite infections, autoimmunity, tumor immunity, and allergic inflammation. The conservation of Th9 phenotype and function across evolution suggests that Th9 cells play a prominent role in effective immunity. In this chapter we outline preclinical mouse studies and human studies that demonstrate a role for Th9/IL-9 in the pathogenesis of atopic disease, colitis, central nervous system paralysis, and protection against helminthic parasite infection and tumor progression. We further outline current therapeutics that might be used to modulate Th9 activity in a clinical setting.

Original languageEnglish (US)
Title of host publicationTranslational Immunology: Mechanisms and Pharmacologic Approaches
PublisherElsevier Inc.
Pages165-184
Number of pages20
ISBN (Print)9780128015773
DOIs
StatePublished - Dec 19 2015

Fingerprint

Interleukin-9
Immunotherapy
Immunity
Parasitic Diseases
Cytokines
Inflammation
Central Nervous System Diseases
T-Lymphocyte Subsets
Colitis
Autoimmunity
Paralysis
Neoplasms
T-Lymphocytes
Phenotype
Therapeutics

Keywords

  • Allergy
  • Asthma
  • Autoimmunity
  • Helminths
  • IL-9
  • T helper cell
  • Therapy
  • Tumor immunity

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Cite this

Awe, O., & Kaplan, M. (2015). Th9 Cells as Targets for Immunotherapy. In Translational Immunology: Mechanisms and Pharmacologic Approaches (pp. 165-184). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-801577-3.00007-1

Th9 Cells as Targets for Immunotherapy. / Awe, O.; Kaplan, Mark.

Translational Immunology: Mechanisms and Pharmacologic Approaches. Elsevier Inc., 2015. p. 165-184.

Research output: Chapter in Book/Report/Conference proceedingChapter

Awe, O & Kaplan, M 2015, Th9 Cells as Targets for Immunotherapy. in Translational Immunology: Mechanisms and Pharmacologic Approaches. Elsevier Inc., pp. 165-184. https://doi.org/10.1016/B978-0-12-801577-3.00007-1
Awe O, Kaplan M. Th9 Cells as Targets for Immunotherapy. In Translational Immunology: Mechanisms and Pharmacologic Approaches. Elsevier Inc. 2015. p. 165-184 https://doi.org/10.1016/B978-0-12-801577-3.00007-1
Awe, O. ; Kaplan, Mark. / Th9 Cells as Targets for Immunotherapy. Translational Immunology: Mechanisms and Pharmacologic Approaches. Elsevier Inc., 2015. pp. 165-184
@inbook{6c0fb0a5a8414e61abb59e3fade00954,
title = "Th9 Cells as Targets for Immunotherapy",
abstract = "The secretion of specific cytokines distinguishes T helper cell subsets and confers the ability of the T cell to promote distinct types of inflammation. The restricted nature of cytokine production among these subsets makes them attractive therapeutic targets. The interleukin (IL)-9-secreting subset termed Th9 cells are observed in patients and in mouse models associated with immunity to parasite infections, autoimmunity, tumor immunity, and allergic inflammation. The conservation of Th9 phenotype and function across evolution suggests that Th9 cells play a prominent role in effective immunity. In this chapter we outline preclinical mouse studies and human studies that demonstrate a role for Th9/IL-9 in the pathogenesis of atopic disease, colitis, central nervous system paralysis, and protection against helminthic parasite infection and tumor progression. We further outline current therapeutics that might be used to modulate Th9 activity in a clinical setting.",
keywords = "Allergy, Asthma, Autoimmunity, Helminths, IL-9, T helper cell, Therapy, Tumor immunity",
author = "O. Awe and Mark Kaplan",
year = "2015",
month = "12",
day = "19",
doi = "10.1016/B978-0-12-801577-3.00007-1",
language = "English (US)",
isbn = "9780128015773",
pages = "165--184",
booktitle = "Translational Immunology: Mechanisms and Pharmacologic Approaches",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Th9 Cells as Targets for Immunotherapy

AU - Awe, O.

AU - Kaplan, Mark

PY - 2015/12/19

Y1 - 2015/12/19

N2 - The secretion of specific cytokines distinguishes T helper cell subsets and confers the ability of the T cell to promote distinct types of inflammation. The restricted nature of cytokine production among these subsets makes them attractive therapeutic targets. The interleukin (IL)-9-secreting subset termed Th9 cells are observed in patients and in mouse models associated with immunity to parasite infections, autoimmunity, tumor immunity, and allergic inflammation. The conservation of Th9 phenotype and function across evolution suggests that Th9 cells play a prominent role in effective immunity. In this chapter we outline preclinical mouse studies and human studies that demonstrate a role for Th9/IL-9 in the pathogenesis of atopic disease, colitis, central nervous system paralysis, and protection against helminthic parasite infection and tumor progression. We further outline current therapeutics that might be used to modulate Th9 activity in a clinical setting.

AB - The secretion of specific cytokines distinguishes T helper cell subsets and confers the ability of the T cell to promote distinct types of inflammation. The restricted nature of cytokine production among these subsets makes them attractive therapeutic targets. The interleukin (IL)-9-secreting subset termed Th9 cells are observed in patients and in mouse models associated with immunity to parasite infections, autoimmunity, tumor immunity, and allergic inflammation. The conservation of Th9 phenotype and function across evolution suggests that Th9 cells play a prominent role in effective immunity. In this chapter we outline preclinical mouse studies and human studies that demonstrate a role for Th9/IL-9 in the pathogenesis of atopic disease, colitis, central nervous system paralysis, and protection against helminthic parasite infection and tumor progression. We further outline current therapeutics that might be used to modulate Th9 activity in a clinical setting.

KW - Allergy

KW - Asthma

KW - Autoimmunity

KW - Helminths

KW - IL-9

KW - T helper cell

KW - Therapy

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=84960830976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960830976&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801577-3.00007-1

DO - 10.1016/B978-0-12-801577-3.00007-1

M3 - Chapter

SN - 9780128015773

SP - 165

EP - 184

BT - Translational Immunology: Mechanisms and Pharmacologic Approaches

PB - Elsevier Inc.

ER -